BROKER MOVES: ALGT upgraded at Raymond James; NXGL downgraded at Maxim
Upgrades:
- Allegiant Travel (ALGT) Upgraded from Outperform to Strong Buy at Raymond James; PT USD 116
- Celestica (CLS) Upgraded from Neutral to Buy at UBS; PT USD 430
- Janux Therapeutics (JANX) Upgraded from Peer Perform to Outperform at Wolfe Research; PT USD 23
- PulteGroup (PHM) Upgraded from Peer Perform to Outperform at Wolfe Research; PT USD 129
- Suzano (SUZ) Upgraded from Neutral to Buy at BofA Securities; PT USD 13
Downgrades:
- NexGel (NXGL) Downgraded from Buy to Hold at Maxim Group
- Weave Communications (WEAV) Downgraded from Outperform to Market Perform at Raymond James
Initiations:
- Aeva Technologies (AEVA) Initiated at Neutral at Goldman Sachs; PT USD 20
- Alvotech (ALVO) Initiated at Buy at BofA Securities; PT USD 7
- Cummins (CMI) Initiated at Outperform at CICC; PT USD 781
- EverQuote (EVER) Initiated at Overweight at JPMorgan; PT USD 29
- Fortune Brands Innovations (FBIN) Initiated at Overweight at Wells Fargo; PT USD 52
- Funko (FNKO) Initiated at Buy at Seaport Global Securities
- Frontdoor (FTDR) Initiated at Neutral at JPMorgan; PT USD 95
- Insight Molecular Diagnostics (IMDX) Initiated at Buy at Lucid Capital Markets; PT USD 8
- Inhibrx Biosciences (INBX) Initiated at Buy at H.C. Wainwright; PT USD 245
- IOND (IOND) Initiated at Buy at BTIG; PT USD 85
- IOND (IOND) Initiated at Buy at Jefferies; PT USD 85
- JMKE (JMKE) Initiated at Buy at TD Cowen; PT USD 26
- JMKE (JMKE) Initiated at Buy at Deutsche Bank; PT USD 27
- JMKE (JMKE) Initiated at Buy at Stifel; PT USD 27
- JMKE (JMKE) Initiated at Buy at BTIG; PT USD 28
- JMKE (JMKE) Initiated at Buy at Guggenheim; PT USD 28
- JMKE (JMKE) Initiated at Buy at UBS; PT USD 28
- JMKE (JMKE) Initiated at Buy at Jefferies; PT USD 29
- JMKE (JMKE) Initiated at Buy at Truist Securities; PT USD 30
- JMKE (JMKE) Initiated at Buy at Loop Capital; PT USD 40
- JMKE (JMKE) Initiated at Equal Weight at Wells Fargo; PT USD 25
- JMKE (JMKE) Initiated at Market Perform at Bernstein SocGen Group; PT USD 26
- JMKE (JMKE) Initiated at Outperform at Evercore ISI; PT USD 28
- JMKE (JMKE) Initiated at Outperform at RBC Capital; PT USD 28
- JMKE (JMKE) Initiated at Outperform at Raymond James; PT USD 29
- JMKE (JMKE) Initiated at Outperform at Mizuho; PT USD 31
- JMKE (JMKE) Initiated at Overweight at JPMorgan; PT USD 26
- JMKE (JMKE) Initiated at Overweight at Morgan Stanley; PT USD 29
- JMKE (JMKE) Initiated at Overweight at Piper Sandler; PT USD 29
- JMKE (JMKE) Initiated at Peer Perform at Wolfe Research
- MediaAlpha (MAX) Initiated at Neutral at JPMorgan; PT USD 15
- Match Group (MTCH) Initiated at Neutral at JPMorgan; PT USD 43
- nCino (NCNO) Initiated at Overweight at Piper Sandler; PT USD 25
- NVCT (NVCT) Initiated at Overweight at Cantor Fitzgerald
- QTTB (QTTB) Initiated at Overweight at Morgan Stanley; PT USD 34
- REF (REF) Initiated at Buy at BTIG; PT USD 20
- REF (REF) Initiated at Buy at Citi; PT USD 20
- REF (REF) Initiated at Buy at Guggenheim; PT USD 20
- REF (REF) Initiated at Equalweight at Morgan Stanley; PT USD 16
- REF (REF) Initiated at Outperform at William Blair
- REF (REF) Initiated at Outperform at RBC Capital; PT USD 18
- REF (REF) Initiated at Overweight at JPMorgan; PT USD 21
- REF (REF) Initiated at Underperform at Telsey; PT USD 20
- Roku (ROKU) Initiated at Neutral at JPMorgan; PT USD 160
- STTK (STTK) Initiated at Strong Buy at Raymond James; PT USD 18
- Talen Energy (TLN) Initiated at Outperform at Mizuho; PT USD 405
- Veeva Systems (VEEV) Initiated at Overweight at Piper Sandler; PT USD 295
- Viemed Healthcare (VMD) Initiated at Outperform at Barrington Research; PT USD 14
- Vistra (VST) Initiated at Outperform at Mizuho; PT USD 169
- Whirlpool (WHR) Initiated at Equal Weight at Wells Fargo; PT USD 42
- Xometry (XMTR) Initiated at Overweight at JPMorgan; PT USD 120
- Clear Secure (YOU) Initiated at Overweight at JPMorgan; PT USD 55
A standard daily ratings roundup, heavy on initiations rather than revisions, which is the less market-moving of the two categories. The dominant feature is a cluster of concurrent initiations on a single name by a dozen-plus banks at tightly grouped price targets, the signature of post-IPO research coverage coming off a quiet period or lockup-adjacent restriction, with underwriters typically leading the coverage wave and non-syndicate houses the outliers at either end. Comparable initiation sweeps tend to converge toward a consensus target quickly, and the dispersion between the top and bottom of the range is the tell for how contested the story is. The single-name upgrades and downgrades, including a two-notch move to a strong buy, are the kind of items that historically move only the individual tape and mostly in small and mid caps where sell-side opinion is thin; in large caps a lone ratings change rarely survives the day unless it breaks from the prevailing consensus. Worth noting is that several initiations carry neutral or equal weight stances alongside the buys, which in past coverage launches has signalled genuine valuation debate rather than a syndicate love-in. The follow-ons are whether the contested names see target revisions after the first earnings print under coverage, which is where initiation theses typically get tested.